Squarepoint
SABS icon

Squarepoint’s SAB Biotherapeutics SABS Stock Holding History

Squarepoint’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$129K Buy
+40,625
New +$148K ﹤0.01% 4168

Other funds holding SABS

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint's SABS Position: Q3 2026 in Review

Squarepoint opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 40,625 shares worth $129K. The stake represents ﹤0.01% of the portfolio and ranks #4168 among its holdings.

26 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Squarepoint held 40,625 shares of SAB Biotherapeutics worth $129K as of Q3 2026.
  • SAB Biotherapeutics was a new Squarepoint position in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4168 holding.
  • 26 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.